Search - tctmd.com

$TCT 1080: First-in-Man Prolonged Pressure-Controlled Intermittent Coronary Sinus Occlusion to Treat Refractory Left Ventricular Dysfunction and Ischemia$

Presentation TCT 2016

TCT 1080: First-in-Man Prolonged Pressure-Controlled Intermittent Coronary Sinus Occlusion to Treat Refractory Left Ventricular Dysfunction and Ischemia

Presenter: Tayo A. Addo, Jose de Ribamar Costa Jr, Francesco Giannini

October 30, 2016

News Industry News

Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes

October 30, 2016

Advertisement

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

Conflict Persists Between Guidelines and Practice When It Comes to Treating CAD in TAVR Candidates

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

Anemia Common in ACS Patients, Linked with Higher Mortality

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

Incomplete Revascularization Linked With Increased MACE in Subsequent Noncardiac Surgery

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

What Makes a Plaque Vulnerable: Morphology, Chemistry, Biologic Activity, or Ischemia?

CMR Subanalysis of EXPLORE May Help Pinpoint Which CTO Regions Benefit From PCI

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Cancer Patients Face Increased Risk of Acute MI, More PCI Complications, Higher Mortality, and Soaring Costs

DEBATE: Predicting Thrombotic Events in Patients With STEMI and Multivessel Disease: The Degree of Stenosis/Ischemia Is Most Important!

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Rationale for and Design of ISCHEMIA: What I Expect the Findings to Be But What Wont Surprise Me!

TCT 1080: First-in-Man Prolonged Pressure-Controlled Intermittent Coronary Sinus Occlusion to Treat Refractory Left Ventricular Dysfunction and Ischemia

Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content